<DOC>
	<DOCNO>NCT00895206</DOCNO>
	<brief_summary>This study open , randomise trial one group patient ( control ) receive golden standard therapy group ( treatment ) receive individually adapt immunosuppression .</brief_summary>
	<brief_title>Individually Adapted Immunosuppression de Novo Renal Transplantation Based Immune Function Monitoring : Prospective Randomised Study</brief_title>
	<detailed_description />
	<criteria>First second kidney transplantation Males female , 18 year old old Women childbearing potential must negative serum urine pregnancy test sensitivity equal least 50 mIU/mL Patients must capable understand purpose risk study must sign informed consent form Multiple organ transplantation ( eg . kidneypancreas , kidneyheart , kidneyliver , ... ) Transplantation patient receive another organ transplant previously except one kidney transplant Recipients HLAidentical livingrelated renal transplant Patients PRA &gt; 10 % , patient lose first graft rejection . Pregnant lactate woman WBC = &lt; 2.5 x 109/L ( IU ) , platelet count = &lt; 100 x 109/L ( IU ) , Hb = &lt; 6g/dl time entry study Active peptic ulcer Severe diarrhea gastrointestinal disorder might interfere ability absorb oral medication , include diabetic patient previously diagnose diabetic gastroenteropathy Known HIV1 HTLV1 positive test History malignancy past 5 year ( exception adequately treat basal squamous skin cell carcinoma ) The use investigational drug immunosuppressive drug specify protocol Patients receive bile acid sequestrants Psychological illness condition interfere patient 's compliance ability understand requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>